ASCO: GSK builds case for return of multiple myeloma drug Blenrep

GSK is strengthening its argument to resume selling its cancer drug Blenrep. Study results released Sunday show adding the therapy to two other backbone multiple myeloma medicines delayed disease progression better than Takeda’s Velcade and the same drug regimen.